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Hyperhomocysteinemia Increases Risk of Death, Especially
in Type 2 Diabetes
5-Year Follow-Up of the Hoorn Study
Ellen K. Hoogeveen, MD, PhD; Pieter J. Kostense, PhD; Cornelis Jakobs, PhD;
Jacqueline M. Dekker, PhD; Giel Nijpels, MD, PhD; Robert J. Heine, MD, PhD;
Lex M. Bouter, PhD; Coen D.A. Stehouwer, MD, PhD
Background—A high serum total homocysteine (tHcy) concentration is a risk factor for death, but the strength of the
relation in patients with type 2 (non–insulin-dependent) diabetes mellitus compared with nondiabetic subjects is not
known. A cross-sectional study suggested that the association between tHcy and cardiovascular disease is stronger in
diabetic than in nondiabetic subjects. We therefore prospectively investigated the combined effect of hyperhomocys-
teinemia and type 2 diabetes on mortality.
Methods and Results—Between October 1, 1989, and December 31, 1991, serum was saved from 2484 men and women,
50 to 75 years of age, who were randomly selected from the town of Hoorn, The Netherlands. Fasting serum tHcy
concentration was measured in 171 subjects who died (cases; 76 of cardiovascular disease) and in a stratified random
sample of 640 survivors (control subjects). Mortality risks were calculated over 5 years of follow-up by means of logistic
regression. The prevalence of hyperhomocysteinemia (tHcy .14 mmol/L) was 25.8%. After adjustment for major
cardiovascular risk factors, serum albumin, and HbA1c, the odds ratio (95% CI) for 5-year mortality was 1.56 (1.07 to
2.30) for hyperhomocysteinemia and 1.26 (1.02 to 1.55) per 5-mmol/L increment of tHcy. The odds ratio for 5-year
mortality for hyperhomocysteinemia was 1.34 (0.87 to 2.06) in nondiabetic subjects and 2.51 (1.07 to 5.91) in diabetic
subjects (P50.08 for interaction).
Conclusions—Hyperhomocysteinemia is related to 5-year mortality independent of other major risk factors and appears
to be a stronger (1.9-fold) risk factor for mortality in type 2 diabetic patients than in nondiabetic subjects. (Circulation.
2000;101:1506-1511.)
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Cardiovascular disease is the major cause of death indiabetic and nondiabetic subjects. The overall and car-
diovascular mortality rates are 2 to 4 times higher in type 2
diabetic patients than in nondiabetic subjects.1–5 Type 2
diabetes is known to be associated with several other cardio-
vascular risk factors, including dyslipidemia and hyperten-
sion, but these do not fully explain the excess mortality rates
in type 2 diabetes. Therefore, increased risk must be due, at
least in part, to diabetes itself, poor metabolic control, or
other factors.
Hyperhomocysteinemia is a recently recognized risk factor
for cardiovascular disease that is independent of major risk
factors such as diabetes, hypertension, hypercholesterolemia,
and smoking.6–9 The prevalence estimates of hyperhomocys-
teinemia (.14 mmol/L) vary between 5% and 30% in the
general population.10–13 Although the mechanisms by which
homocysteine promotes atherothrombosis are unknown, the
epidemiological evidence for the association of hyperhomo-
cysteinemia with atherothrombotic disease is strong.6,7,14 A
meta-analysis15 showed that treatment with 0.5 to 5.0 mg
folic acid daily can lower serum total homocysteine (tHcy) by
15% to 40% within ’6 weeks. In addition, it has been
estimated that lowering tHcy by 5 mmol/L (’1 SD) may
reduce the risk of cardiovascular death by ’10%.7 Taken
together, hyperhomocysteinemia may be an important modi-
fiable risk factor, although this must be confirmed in random-
ized studies of homocysteine-lowering treatment.
In a cross-sectional analysis, hyperhomocysteinemia ap-
peared to be a stronger risk factor for cardiovascular disease
in type 2 diabetic subjects than in nondiabetic subjects.13
Such an interaction between hyperhomocysteinemia and type
2 diabetes with regard to cardiovascular risk may be clinically
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important, as it implies that homocysteine-lowering treatment
may be especially effective in type 2 diabetes. In view of
these considerations, we investigated the combined effect of
hyperhomocysteinemia and diabetes with respect to 5-year
risk of death in a population-based study.
Methods
Design and Study Population
The Hoorn Study is a prospective study of glucose tolerance and
other cardiovascular risk factors in a 50- to 75-year-old general white
population. The baseline examination was conducted from October
1, 1989, until December 31, 1991.16 Briefly, a random sample of all
men and women 50 to 75 years of age was drawn from the municipal
population registry office of Hoorn, The Netherlands; 2484 subjects
were enrolled in this cohort (response rate 71%). All subjects, except
previously diagnosed diabetic subjects treated with oral glucose-
lowering agents or insulin, underwent a 75-g oral glucose tolerance
test (OGTT) and were classified according to the World Health
Organization (1985) criteria.17 A second OGTT (participation rate
93%) was performed for reasons of efficiency in a random sub-
sample (n51122) stratified by 2-hour glucose values of the first test,
age, and sex. Finally, from this subsample, an age-stratified, sex-
stratified, and glucose tolerance–stratified random subsample
(n5715), the “subcohort,” was drawn. Glucose tolerance was di-
vided into 3 categories on the basis of the mean of the 2 OGTTs:
NGT, (n5334), IGT, (n5197), and type 2 diabetes mellitus
(n5184).
A case-control study nested within the cohort was carried out. The
survivors of the subcohort (as defined above) served as control
subjects. Every subject who died within 5 years of follow-up of the
entire cohort was ascertained and selected for the present study.
Information on subjects’ vital status on January 1, 1997, was
collected from the mortality registry of the municipality of Hoorn.
Information on vital status of 137 subjects who moved out of town
was obtained from the new local municipalities. We determined
whether each subject had died during or survived the first 5 years of
follow-up. Causes of death were extracted from medical records of
the general practitioners and the hospital of Hoorn, verified by a
physician, and classified according to the 9th revision of the
International Classification of Diseases (ICD).18 Death from cardio-
vascular disease was defined by ICD codes 390-459.
During the 5-year follow-up, 172 participants died, 75 of whom
were included in the subcohort (n5715). No serum was available for
the measurement of tHcy from 1 of the subjects who died. Thus,
analyses were performed on 811 subjects, and tHcy was measured in
stored sera. The Hoorn Study was approved by the Ethics Review
Committee of the University Hospital Vrije Universiteit Amsterdam.
Informed consent was obtained from all participants.
Measurement of tHcy
Fasting blood samples were centrifuged within 1 hour after collec-
tion. Serum was stored at 220°C for 4 to 7 years. There is good
evidence that serum tHcy concentrations are stable for $10 years.19
Serum total (free plus protein bound) homocysteine was measured
with tri-n-butylphosphine as the reducing agent and ammonium
7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonate as the thiol-specific
fluorochromophore, followed by high-performance liquid chroma-
tography with fluorescence detection.20 The intra-assay and interas-
say coefficients were 2.1% and 5.1%.
Other Variables
Blood pressure was measured as the mean of 4 measurements taken
on 2 different occasions with the use of a random-zero sphygmoma-
nometer under standardized conditions. Fasting and 2-hour postload
venous plasma glucose concentrations were measured with a glucose
dehydrogenase method (Merck). Fasting serum total cholesterol,
HDL-cholesterol, and triglycerides were measured by enzymatic
techniques (Boehringer-Mannheim). Serum albumin was assessed
with the bromcresol purple method. Hypoalbuminemia was defined
as albumin #34 g/L.21 All laboratory measurements were carried out
in a blinded fashion with respect to mortality, glucose tolerance
status, and other clinical data.
Statistical Analysis
Prevalence of hyperhomocysteinemia, defined as serum tHcy level
.14 mmol/L,12 in the entire cohort was back-calculated by means of
direct standardization. Briefly, the prevalence of hyperhomocys-
teinemia was determined in 24 strata [age (50 to 59, 60 to 69, and 70
to 75 years), sex (male and female), and glucose tolerance (NGT,
IGT, and newly diagnosed and known type 2 diabetes mellitus)] of
the subsample. To assess the prevalence of hyperhomocysteinemia in
the original population-based sample (standard n52484), the prev-
alence of hyperhomocysteinemia was back-calculated from the
magnitude of each age, sex, and glucose tolerance category stratum.
We assessed the relation between tHcy and 5-year overall mor-
tality in the nested case-control study with logistic regression
analyses. We calculated odds ratios plus 95% CI for serum tHcy both
as a continuous variable, expressed per 5-mmol/L (’1 SD) incre-
ment of serum tHcy, and as a categorical variable [divided in 2
(.14 mmol/L vs #14 mmol/L) and in 4 categories (#9.0 mmol/L,
9.1 to 14.0 mmol/L, 14.1 to 19.0 mmol/L and .19.0 mmol/L)]. Odds
ratios of mortality were adjusted for the stratifying variables (ie, age,
sex, and glucose tolerance) and potentially confounding major
cardiovascular risk factors (ie, hypertension, hypercholesterolemia,
and current smoking11,22). Possible interactions between tHcy and
cardiovascular risk factors were assessed in stratified analyses and
with interaction terms by means of logistic regression.
To assess whether the observations were distorted by underlying
disease that might cause both high values of serum tHcy and
increased mortality rates,23 we did 2 additional analyses. First, we
adjusted for serum albumin, an acute-phase protein and a putative
marker of health and nutrition status.24 Second, we adjusted for the
presence of cardiovascular disease at baseline, as defined else-
where,13 although the latter analysis might obscure a true effect
because cardiovascular disease may well be an intermediate factor in
the causal pathway linking tHcy to mortality.25
Finally, we assessed the relation between tHcy and cardiovascular
death over the first 5-years of follow-up. This analysis was restricted
to the subcohort because it required the Cox proportional hazards
model. All analyses were performed with SPSS for Windows 95
version 7.5.2.
Results
The baseline characteristics of the patients who died and the
control subjects are presented in Table 1. The back-calculated
prevalence of hyperhomocysteinemia (.14 mmol/L) in the
cohort was 25.8%. Of all type 2 diabetic subjects, 115
(62.5%) were newly diagnosed and 69 (37.5%) were known
to have diabetes and were treated with glucose-lowering
agents: 16 (8.7%) with insulin, 52 (28.3%) with sulfonyl-
ureas, and 3 (1.6%) with metformin (of whom 2 also used
sulfonylureas). The median known duration of diabetes of
subjects in whom type 2 diabetes had previously been
diagnosed was 6.4 years (interquartile range 2.7 to 12.0).
Serum tHcy concentrations did not correlate with fasting
glucose (r50.001; P51.0), HbA1c (r520.03; P50.4), or
serum albumin (r520.03; P51.0). The mean serum tHcy
concentration in diabetic subjects treated with insulin or
glucose-lowering agents was 12.3 mmol/L (SD 8.6 mmol/L)
versus 12.5 mmol/L (SD 4.6 mmol/L) in those not so treated
(P50.1); it was 12.3 mmol/L (SD 4.2 mmol/L) in subjects
treated with insulin and 12.3 mmol/L (SD 9.6 mmol/L) in
those treated with glucose-lowering agents (P50.4).
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The cause of death could be found in 93.6% (160 of 171);
47.5% (76 of 160) died of cardiovascular disease, of whom 34
belonged to the subcohort. The 84 (52.5%) noncardiovascular
deaths were due to malignant neoplasms (60), septicemia (3),
respiratory tract infection (3), respiratory disease (1), external
causes (3), and other causes (14).
In the entire cohort, the 5-year risk of death was 5.7% in
subjects with normal glucose tolerance (NGT), 7.1% in
subjects with impaired glucose tolerance (IGT), and 18.5%
in subjects with diabetes; it was 5.5% in subjects with
serum tHcy #14 mmol/L and 10.8% in subjects with serum
tHcy .14 mmol/L.
The risk of 5-year overall mortality increased considerably
above a serum tHcy concentration of 14 mmol/L (Figure 1).
Table 2 shows the odds ratios of overall mortality in the
presence versus the absence of other major cardiovascular
risk factors. Additional adjustment for dyslipidemia, body
mass index, or pack-years of smoking did not attenuate the
strength of the association between serum tHcy and death, nor
did additional adjustment for serum albumin (Table 2). There
was a graded inverse relation between serum albumin and
death that was not altered by adjustment for potential con-
founders (Table 2). Subjects with hypoalbuminemia had a
2.2-fold (95% CI 1.2 to 3.9) greater risk of death compared
with subjects with serum albumin levels .34 g/L.
We evaluated possible interaction and did not observe
substantial differences among the strata of the following
risk factors: male sex, hypertension, hypercholesterolemia,
and current smoking (data not shown). After stratification
by diabetes and adjustment for age, sex, hypertension,
current smoking, hypercholesterolemia, and serum albu-
min in the logistic regression model, the odds ratio of
5-year mortality associated with hyperhomocysteinemia
was, however, 1.34 (0.87 to 2.06) in nondiabetic subjects
and 2.51 (1.07 to 5.91) in diabetic subjects (P50.08 for
interaction; Figures 2 and 3). This indicates that hyperho-
mocysteinemia is a stronger (1.9-fold, 95% CI 0.7 to 4.9)
risk factor for death in diabetic than in nondiabetic
subjects. For each 5-mmol/L increment of serum tHcy, the
odds ratio was 1.17 (0.92 to 1.50) in nondiabetic subjects
and 1.60 (1.02 to 2.51) in diabetic subjects. (Subjects with
NGT and IGT were pooled because the odds ratio of 5-year
mortality associated with hyperhomocysteinemia did not
differ substantially between these categories and the odds
ratio remained similar if NGT and IGT were pooled; data
not shown.) An additional analysis revealed that among
diabetic subjects with hyperhomocysteinemia, those with
known diabetes had the highest relative risk of mortality.
After adjustment for age and sex, the odds ratio of 5-year
mortality associated with hyperhomocysteinemia was 2.58
(0.90 to 7.40) for subjects with newly diagnosed diabetes
and 3.18 (0.74 to 13.74) for subjects with known diabetes.
This interaction showed a significant trend (P50.04): The
odds ratio increased gradually over the 3 subgroups:
nondiabetic, newly diagnosed diabetic, and known diabetic
subjects. Finally, in a stratified analysis, after adjustment
for cardiovascular risk factors and the presence of cardio-
vascular disease at baseline, we again found interaction:
The odds ratio of 5-year mortality associated with hyper-
homocysteinemia was 1.27 (0.82 to 1.96) in nondiabetic
subjects and 2.55 (1.08 to 6.02) in diabetic subjects
(P50.07 for interaction).
TABLE 1. Baseline Characteristics of the Study Population
Cases† Control Subjects‡
n 171 640
Men,* % 58.5 46.4
Age,* y 66.6 (7.1) 63.9 (7.0)
Body mass index, kg/m2 26.7 (4.2) 27.2 (4.0)
Cigarette smokers, current, % 41.4 27.9
Systolic blood pressure, mm Hg 141 (23) 139 (19)
Diastolic blood pressure, mm Hg 82 (12) 82 (10)
Hypertension,§ % 50.3 37.3
Impaired glucose tolerance,* % 10.5 28.1
Diabetes mellitus,* % 22.2 22.8
Plasma fasting glucose, mmol/L 6.6 (2.9) 6.5 (2.2)
HbA1c, % of hemoglobin 6.0 (1.4) 5.8 (1.2)
Serum total cholesterol, mmol/L 6.7 (1.1) 6.7 (1.2)
Hypercholesterolemia,\ % 61.4 54.1
Serum HDL cholesterol, mmol/L 1.2 (0.4) 1.3 (0.4)
Total:HDL cholesterol ratio 5.9 (1.8) 5.5 (1.7)
Serum triglycerides, mmol/L 1.6 (1.2-2.2) 1.5 (1.1-2.1)
Dyslipidemia,¶ % 42.7 33.0
Serum albumin, g/L 38 (3.2) 39 (2.9)
Serum total homocysteine, mmol/L 12.9 (9.9-16.2) 11.5 (9.4-14.1)
Data are presented as mean (SD), percentage of the total, or median
(interquartile range).
*Stratifying variable.
†Cases are subjects who died during the 5-year follow-up.
‡Control subjects are survivors taken from an age-stratified, sex-stratified,
and glucose tolerance–stratified random sample of the cohort (see Methods).
§Hypertension was defined as blood pressure $160 mm Hg systolic and/or
$95 mm Hg diastolic and/or current use of antihypertensive medication.
\Hypercholesterolemia was defined as total cholesterol $6.5 mmol/L and/or
current use of cholesterol-lowering medication.
¶Dyslipidemia was defined as levels of triglycerides .2.3 mmol/L and/or
levels of HDL cholesterol ,1.0 mmol/L in men and ,1.1 mmol/L in women.
Figure 1. Odds ratios for 5-year overall death according to
serum tHcy level adjusted for age, sex, diabetes, hypertension,
hypercholesterolemia, current smoking, serum albumin, and
HbA1c. Reference category was serum tHcy values 9.1 to
14.0 mmol/L. Percentages of population under study for each
serum tHcy range are shown. Error bars represent upper half of
95% CI (P50.04 for trend).
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The mean serum tHcy concentration did not differ between
subjects who died of cardiovascular and noncardiovascular
causes (13.9 mmol/L, SD 6.5 mmol/L, and 13.5 mmol/L, SD
5.0 mmol/L; P50.6) but was higher in subjects who died of
cardiovascular disease compared with those who survived the
first 5 years of follow-up (13.9 mmol/L, SD 6.5 mmol/L, and
12.6, SD 5.9 mmol/L; P50.006).
After adjustment for the stratifying variables, the hazard
ratio (95% CI) of cardiovascular death was 1.65 (0.81 to 3.31)
for hyperhomocysteinemia, 1.58 (1.04 to 2.42) for each
category increment of serum tHcy, and 1.55 (1.08 to 2.23) for
each 5-mmol/L increment of serum tHcy. After additional
adjustment for hypertension, hypercholesterolemia, and cur-
rent smoking, these hazard ratios were 1.60 (0.65 to 3.01),
1.51 (0.98 to 2.32), and 1.45 (1.01 to 2.08), respectively.
Because of the limited number of cases in the subcohort, we
could not investigate the issue of interaction of hyperhomo-
cysteinemia and diabetes with regard to cardiovascular death.
Discussion
This prospective, population-based study, with a 5-year
follow-up, indicates that hyperhomocysteinemia is a risk
factor for overall mortality in type 2 diabetic patients,
independent of major cardiovascular risk factors and serum
albumin, a putative general marker of health. Moreover,
hyperhomocysteinemia appeared to be a stronger (’2-fold)
risk factor for death in diabetic than in nondiabetic subjects.
For each 5-mmol/L (’1 SD) increment of serum tHcy, the
risk of 5-year mortality rose by 17% in the nondiabetic and by
60% in the diabetic subjects.
TABLE 2. Odds Ratios (95% CI) for 5-Year Overall Mortality
Risk Factors
Adjusted for Age,
Sex, and Diabetes
Adjusted for Age,
Sex, Diabetes,
and Other Risk Factors*
Hyperhomocysteinemia (.14 vs #14 mmol/L) 1.58 (1.09–2.28)† 1.56 (1.07–2.30)
Total homocysteine (per category increment)‡ 1.31 (1.06–1.63) 1.27 (1.02–1.59)
Total homocysteine (per 5-mmol/L increment)§ 1.31 (1.06–1.60) 1.26 (1.02–1.55)
Hypertension (yes/no) 1.60 (1.12–2.28) 1.58 (1.08–2.29)
Current smoking (yes/no) 2.01 (1.39–2.90) 1.66 (1.13–2.45)
Hypercholesterolemia (yes/no)\ 1.49 (1.04–2.13) 1.45 (1.00–2.11)
Serum albumin (per 2.5-g/L increment) 0.72 (0.62–0.84) 0.73 (0.63–0.86)
HbA1c (per % increment) 1.24 (1.05–1.48) 1.17 (0.98–1.40)
*Adjusted for age, sex, diabetes, and the other 5 risk factors mentioned in this table. When these
analyses were adjusted for homocysteine, homocysteine was entered as a 4-category variable in the
models.
†After additional adjustment for dyslipidemia: 1.58 (1.09 to 2.29) or for body mass index: 1.54
(1.06 to 2.23).
‡Serum total homocysteine was divided into 4 categories (see Methods).
§After exclusion of 8 outliers (1 case and 7 control subjects with serum total homocysteine
.35 mmol/L); if outliers were included, the odds ratios were 1.10 (0.96 to 1.25) and 1.10 (0.95 to
1.26).
\If hypercholesterolemia was replaced by total:HDL cholesterol ratio, odds ratios were 1.18 (1.07
to 1.31) and 1.12 (1.01 to 1.24).
Figure 2. Odds ratios for 5-year overall death associated with
hyperhomocysteinemia (.14 mmol/L) after stratification by dia-
betes (yes/no). Error bars represent upper half of 95% CI. Odds
ratios are adjusted for age, sex, hypertension, hypercholesterol-
emia, current smoking, and serum albumin (*P,0.05, P50.08
for interaction).
Figure 3. Estimated survival among type 2 diabetic subjects in
subcohort (see Methods), according to presence of hyperhomo-
cysteinemia (yes/no). Survival was estimated with Kaplan-Meier
product-limit method compared with log-rank test.
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There are several prospective studies that have investigated
the relation between tHcy and risk of cardiovascular disease.
Many9,26–36 but not all23,37,38 found a positive relation. None
of the previous studies, however, investigated the possibility
of interaction between hyperhomocysteinemia and diabetes
with regard to risk of death. The design of the present study,
with a high prevalence and an accurate diagnosis of type 2
diabetes, provided an opportunity to do so. The strength of
the relation between hyperhomocysteinemia and death ap-
peared to be stronger among those with diabetes than among
those without diabetes. An interaction of hyperhomocysteine-
mia with diabetes is biologically plausible. High homocys-
teine concentrations may exert an atherothrombotic effect
through increasing oxidative stress, which may induce endo-
thelial dysfunction.14,39–41 Homocysteine can also affect the
properties of the extracellular matrix and increase smooth
muscle cell proliferation.14 Oxidative stress is thought to be
increased in type 2 diabetes,42 and matrix alterations are a
prominent feature of diabetes in general, both of which might
make diabetes patients more susceptible to the adverse affect
of hyperhomocysteinemia. The interaction with hyperhomo-
cysteinemia observed in the present study, if confirmed, may
have important implications with regard to risk management
in type 2 diabetes.
Little is known about the impact of diabetes per se or its
treatment on tHcy metabolism.13,43 In the present study, we
found no relation between tHcy and fasting glucose or HbA1c.
However, ’40% of the diabetic subjects had previously been
diagnosed, and we therefore cannot rule out that changes of
dietary habits may have resulted in an increase of vitamin B
intake.
The present study has several limitations. (1) We lacked
data on intake and serum levels of folate, vitamin B12, and
vitamin B6. We therefore were unable to explore the extent to
which the relation between B vitamins and serum tHcy levels
differs for diabetic and nondiabetic subjects. It has been
suggested that hyperglycemia may cause an increased loss of
water-soluble B vitamins.44 On the other hand, relative renal
hyperfiltration among diabetic subjects may result in lower
tHcy levels.45 (2) As in any study, our data were subject to
classification errors. Errors in coding cause of death would
not affect our analyses of overall mortality, but they would
affect the count of deaths from specific causes such as
cardiovascular deaths. Such errors are not likely to be related
to tHcy assessment, however, and therefore will result in
nondifferential misclassification, tending to underestimate the
strength of the relation between hyperhomocysteinemia and
cardiovascular death.25 In addition, owing to small numbers,
we could not assess the effect of hyperhomocysteinemia for
cardiovascular death as precisely as for overall mortality.
(3) Because the follow-up period was relatively short (5
years), we cannot exclude the possibility that tHcy levels are
elevated because of the presence of (sub)clinical atheroscle-
rosis.23,46 However, adjustment for cardiovascular disease at
baseline or serum albumin did not attenuate the relation
between hyperhomocysteinemia and mortality. (4) Finally,
we cannot rule out the possibility that incomplete adjustment
for some cardiovascular risk factors may have resulted in
residual confounding.
In conclusion, this study indicates that hyperhomocysteine-
mia is a risk factor for overall mortality and for cardiovas-
cular death during a 5-year follow-up. The effect does not
appear to be explained by other major cardiovascular risk
factors. It is likely to be a stronger risk factor for overall
mortality in diabetic patients than among nondiabetic sub-
jects. Nevertheless, although strong evidence from this and
other studies has accumulated linking hyperhomocysteinemia
to cardiovascular disease, persuasive inferences about a
causal role will likely emerge only from large randomized
trials in which subjects are allocated to either homocysteine-
lowering therapy or standard preventive approaches.
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